Kivala

Abacavir, the active ingredient in Kivala, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as an oral tablet for oral use. It is combined with lamivudine to treat HIV-1 infection in adults and adolescents, helping to suppress viral replication as part of antiretroviral therapy and is approved in the European Union for this indication.

GNH USA supplies Kivala as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and research institutions, with a focus on quality and regulatory compliance.

Abacavir/lamivudine is used in antiretroviral therapy for HIV-1 infection.

- HIV-1 infection (treatment‑naïve adults): provides viral suppression when combined with other antiretrovirals. - HIV-1 infection (treatment‑experienced patients): offers an alternative NRTI backbone in salvage regimens. - HIV-1 infection (pediatric patients ≥3 years): used as part of combination therapy to control viral replication.

Abacavir/lamivudine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Fatigue: general tiredness. - Diarrhea: loose stools. - Vomiting: occasional emesis. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Hypersensitivity reaction: fever, rash, organ involvement. - Severe liver injury: jaundice, elevated enzymes. - Lactic acidosis: metabolic disturbance. - Neutropenia: reduced white blood cells. - Stevens‑Johnson syndrome: severe skin blistering. - Severe skin reactions: toxic epidermal necrolysis.

When prescribing abacavir/lamivudine, clinicians should consider several safety aspects.

- Renal function: assess baseline and monitor periodically. - Hepatic function: monitor liver enzymes during therapy. - Cardiovascular risk: evaluate history of hypersensitivity reactions. - Pregnancy: use only if benefits outweigh potential risks. - Drug resistance: avoid monotherapy to prevent viral resistance. - Store at ambient temperature: keep in the original container, protect from moisture.

Abacavir/lamivudine can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Ritonavir‑boosted protease inhibitors: may raise abacavir plasma levels.

Moderate Interactions (Monitor Closely): - Methadone: possible reduction in opioid effect. - Alcohol: may exacerbate liver toxicity. - Other NRTIs: overlapping toxicity should be monitored.